NCT02910401View on ClinicalTrials.gov

Clinical Response to Rhinovirus Challenge

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

September 21, 2022

Study Completion Date

September 21, 2022

Conditions
AsthmaAllergic Rhinitis
Interventions
BIOLOGICAL

Rhinovirus (GMP RV16 HRV-16)

300 tissue culture infectious dose (TCID)50 mg/ml intranasal one time only

Trial Locations (1)

22908

University of Virginia Health System, Charlottesville

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

University of Virginia

OTHER

NCT02910401 - Clinical Response to Rhinovirus Challenge | Biotech Hunter | Biotech Hunter